EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Efficacy, safety, and dose-response effects of calcifediol supplementation on 25-hydroxyvitamin D, parathyroid hormone, and 1,25-dihydroxyvitamin D levels in healthy adults

Liza Das, Michael F Holick, Naresh Sachdeva, Sanjay Kumar Bhadada, Shallu Singhmar, Neetika Thakur, Pinaki Dutta, Raman Kumar Marwaha

Indian Journal of Pharmacology · 2023

DOI: 10.4103/ijp.ijp_873_22 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Indian Journal of Pharmacology, 2023. Verfasst von Liza Das und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Calcifediol, Vitamin D Deficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vitamin D deficiency (VDD) is highly prevalent across the globe. Cholecalciferol (Vitamin D3) fails to attain sufficient serum concentrations of 25-hydroxyvitamin D (25(OH)D) in a significant proportion of supplemented individuals. Calcifediol (25-hydroxyvitamin D3) is less studied in healthy adults and its effects on 25(OH)D, parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D (1,25(OH)2D) at higher doses are not well known. MATERIALS AND METHODS: The study was an open-label, interventional trial recruiting consecutive participants with VDD who were allocated to receive either 2 capsules (50 μg-group) or 1 capsule (25 μg-group) daily doses of calcifediol. Baseline assessment included clinicodemographic parameters, dietary calcium, calcemic (calcium, inorganic phosphate, albumin, alkaline phosphatase, urine spot calcium/creatinine), and hormonal parameters (25(OH)D, PTH, and 1,25(OH)2D). Participants were followed up at 4 and 8 weeks with repeat assessments of calcemic and hormonal parameters. RESULTS: There were 64 participants, 35 (50 μg-group) and 29 (25 μg-group), without any significant difference in any of the baseline parameters. 97.1% participants in the 50 μg-group (at 4 and 8 weeks) and 93.1% (at 4 weeks) and 96.5% (at 8 weeks) in the 25 μg-group attained 25(OH)D sufficiency (≥30 ng/ml) with calcifediol. The mean serum 25(OH)D was 84.0 ± 27.7 ng/ml in the 50 μg-group and 58.0 ± 23.6 ng/ml in the 25 μg-group group at 4 weeks, which later rose to 94.3 ± 21.8 ng/ml and 76.0 ± 16.4 ng/ml, respectively, at 8 weeks. PTH levels decreased in both groups at both time points. 1,25(OH)2D rose significantly in both groups at 4 and 8 weeks but was not significantly different between both groups. There was no case of incident hypercalcemia or symptomatic nephrolithiasis. CONCLUSION: Calcifediol is a safe and efficacious alternative for oral Vitamin D supplementation in young adults. Increment in 25(OH)D levels is rapid and dose-dependent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalcifediolVitamin D DeficiencyHumansYoung AdultCalciumCholecalciferolDietary SupplementsParathyroid HormonePilot ProjectsVitamin D

Stichwörter der Autor:innen

125-dihydroxyvitamin D25-hydroxyvitamin DVitamin D supplementationcalcifediolparathyroid hormone

Substanzen

1,25-dihydroxyvitamin D25-hydroxyvitamin DCalcifediolCalciumCholecalciferolParathyroid HormoneVitamin D

Autor:innen und Institutionen

  • Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Medicine, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Endocrinology, Society of Endocrine Health Care for Elderly, Adolescents and Children, New Delhi, India.

Zitieren

APA

Das, L., Holick, M. F., Sachdeva, N., Bhadada, S. K., Singhmar, S., Thakur, N., Dutta, P., & Marwaha, R. K. (2023). Efficacy, safety, and dose-response effects of calcifediol supplementation on 25-hydroxyvitamin D, parathyroid hormone, and 1,25-dihydroxyvitamin D levels in healthy adults. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_873_22

Vancouver

Das L, Holick MF, Sachdeva N, Bhadada SK, Singhmar S, Thakur N, et al. Efficacy, safety, and dose-response effects of calcifediol supplementation on 25-hydroxyvitamin D, parathyroid hormone, and 1,25-dihydroxyvitamin D levels in healthy adults. Indian Journal of Pharmacology. 2023. doi:10.4103/ijp.ijp_873_22

BibTeX
@article{Das2023,
  author = {Das, Liza and Holick, Michael F and Sachdeva, Naresh and Bhadada, Sanjay Kumar and Singhmar, Shallu and Thakur, Neetika and Dutta, Pinaki and Marwaha, Raman Kumar},
  title = {Efficacy, safety, and dose-response effects of calcifediol supplementation on 25-hydroxyvitamin D, parathyroid hormone, and 1,25-dihydroxyvitamin D levels in healthy adults},
  journal = {Indian Journal of Pharmacology},
  year = {2023},
  doi = {10.4103/ijp.ijp_873_22}
}
Kostenlos starten →